Fig. 5
HzMUC1-MMAE impairs the growth of CFPAC-1 cell derived xenograft tumors. BALB/c nu/nu mice were subcutaneously injected with CFPAC-1 cells to induce tumor formation. Once the tumors reached 150 mm3 in volumes, the mice were randomized into two groups (seven mice/group) and treated with PBS (n = 7) or HzMUC1-MMAE (5 mg/kg, n = 7) by intravenous injection three times (once every 6-day). A HzMUC1-MMAE dosing scheme. B Body weights of mice for each treatment group. C The growth of tumor volumes over the experimental period. D Images of isolated tumors from mice euthanized at the end of experimental period. E Tumor weights for each treatment group. Statistical analyses were performed using unpaired two-tailed Student’s t-test. *P < 0.05, **P < 0.01, the HzMUC1-MMAE group was compared with that of PBS control group